Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Tumor Biology
Erschienen in: Tumor Biology 2/2014

01.02.2014 | Review

Role of dysregulated expression of leptin and leptin receptors in colorectal carcinogenesis

verfasst von: Shahab Uddin, Azhar R. Hussain, Omar S. Khan, Khawla S. Al-Kuraya

Erschienen in: Tumor Biology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Leptin is a multifunctional adipose-derived cytokine that plays a critical role in bodyweight homeostasis and energy balance. Plasma level of leptin is an indicator of the amount of energy stored in adipose tissues. Recently, leptin and leptin receptor dysregulation have been reported in a variety of malignant cells including colorectal cancers (CRCs). There are growing evidence that leptin may be the link between obesity and CRC carcinogenesis. Leptin influence the growth and proliferation of cancer cells via activation of various growth and survival signaling pathways including JAK/STAT, PI3-kinase/AKT, and/or MAP kinases. In this review, current understanding of leptin and its receptor’s roles in the pathogenesis of colonogenic cancer has been described.
Literatur
1.
Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, et al. Identification and expression cloning of a leptin receptor, Ob-R. Cell. 1995;83:1263–71.PubMedCrossRef
2.
Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425–32.PubMedCrossRef
3.
Gorska E, Popko K, Stelmaszczyk-Emmel A, Ciepiela O, Kucharska A, Wasik M. Leptin receptors. Eur J Med Res. 2010;15 Suppl 2:50–4.PubMed
4.
Jung CH, Kim MS. Molecular mechanisms of central leptin resistance in obesity. Arch Pharm Res. 2013;36:201–7.PubMedCrossRef
5.
6.
Guffey CR, Fan D, Singh UP, Murphy EA. Linking obesity to colorectal cancer: recent insights into plausible biological mechanisms. Curr Opin Clin Nutr Metab Care. 2013;16:595–600.PubMedCrossRef
7.
Ogden CL, Carroll MD, Kit BK, Flegal KM. prevalence of obesity and trends in body mass index among us children and adolescents, 1999–2010. JAMA, J Am Med Assoc. 2012;307:483–90.CrossRef
8.
Sun Z, Dragon S, Becker A, Gounni AS. Leptin inhibits neutrophil apoptosis in children via erk/nf-kappab-dependent pathways. PloS one. 2013;8:e55249.PubMedCentralPubMedCrossRef
9.
Sheffield L. Malignant transformation of mammary epithelial cells increases expression of leptin and leptin receptor. Endocr Res. 2008;33:111–8.PubMedCrossRef
10.
Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. American Cancer S: cancer statistics, 2004. CA Cancer J Clin. 2004;54:8–29.PubMedCrossRef
11.
Golan T, Urban D, Berger R, Lawrence YR. Changing prognosis of metastatic colorectal adenocarcinoma: differential improvement by age and tumor location. Cancer. 2013;119:3084–91.PubMedCrossRef
12.
Boeing H. Obesity and cancer–the update 2013. Best Pract Res Clin Endocrinol Metab. 2013;27:219–27.PubMedCrossRef
13.
14.
Terry PD, Miller AB, Rohan TE. Obesity and colorectal cancer risk in women. Gut. 2002;51:191–4.PubMedCrossRef
15.
Stattin P, Lukanova A, Biessy C, Soderberg S, Palmqvist R, Kaaks R, et al. Obesity and colon cancer: does leptin provide a link? Int J Cancer. 2004;109:149–52.PubMedCrossRef
16.
Sinicrope FA, Foster NR, Sargent DJ, O’Connell MJ, Rankin C. Obesity is an independent prognostic variable in colon cancer survivors. Clin Cancer Res. 2010;16:1884–93.PubMedCentralPubMedCrossRef
17.
Bray GA. Medical consequences of obesity. J Clin Cancer Endocrinol Metab. 2004;89:2583–9.CrossRef
18.
Liefers SC, te Pas MF, Veerkamp RF, van der Lende T. Associations between leptin gene polymorphisms and production, live weight, energy balance, feed intake, and fertility in holstein heifers. J Dairy Sci. 2002;85:1633–8.PubMedCrossRef
19.
20.
Gonullu G, Kahraman H, Bedir A, Bektas A, Yucel I. Association between adiponectin, resistin, insulin resistance, and colorectal tumors. Int J Colorectal Dis. 2010;25:205–12.PubMedCrossRef
21.
Erkasap N, Ozkurt M, Erkasap S, Yasar F, Uzuner K, Ihtiyar E, et al. Leptin receptor (Ob-R) mRNA expression and serum leptin concentration in patients with colorectal and metastatic colorectal cancer. Braz J Med Biol Res. 2013;46:306–10.PubMedCrossRef
22.
Tutino V, Notarnicola M, Guerra V, Lorusso D, Caruso MG. Increased soluble leptin receptor levels are associated with advanced tumor stage in colorectal cancer patients. Anticancer Res. 2011;31:3381–3.PubMed
23.
Song M, Zhang X, Wu K, Ogino S, Fuchs CS, Giovannucci EL, Chan AT. Plasma adiponectin and soluble leptin receptor and risk of colorectal cancer: a prospective study. Cancer Prev Res 2013
24.
Paik SS, Jang SM, Jang KS, Lee KH, Choi D, Jang SJ. Leptin expression correlates with favorable clinicopathologic phenotype and better prognosis in colorectal adenocarcinoma. Ann Surg Oncol. 2009;16:297–303.PubMedCrossRef
25.
Abolhassani M, Aloulou N, Chaumette MT, Aparicio T, Martin-Garcia N, Mansour H, et al. Leptin receptor-related immune response in colorectal tumors: the role of colonocytes and interleukin-8. Cancer Res. 2008;68:9423–32.PubMedCrossRef
26.
Aloulou N, Bastuji-Garin S, Le Gouvello S, Abolhassani M, Chaumette MT, Charachon A, et al. Involvement of the leptin receptor in the immune response in intestinal cancer. Cancer Res. 2008;68:9413–22.PubMedCrossRef
27.
Koda M, Sulkowska M, Kanczuga-Koda L, Surmacz E, Sulkowski S. Overexpression of the obesity hormone leptin in human colorectal cancer. J Clin Pathol. 2007;60:902–6.PubMedCrossRef
28.
Fenton JI, Lavigne JA, Perkins SN, Liu H, Chandramouli GV, Shih JH, et al. Microarray analysis reveals that leptin induces autocrine/paracrine cascades to promote survival and proliferation of colon epithelial cells in an apc genotype-dependent fashion. Mol Carcinog. 2008;47:9–21.PubMedCrossRef
29.
Fenton JI, Hursting SD, Perkins SN, Hord NG. Interleukin-6 production induced by leptin treatment promotes cell proliferation in an apc (min/+) colon epithelial cell line. Carcinogenesis. 2006;27:1507–15.PubMedCrossRef
30.
FitzGerald AJ, Mandir N, Goodlad RA. Leptin, cell proliferation and crypt fission in the gastrointestinal tract of intravenously fed rats. Cell Prolif. 2005;38:25–33.PubMedCrossRef
31.
Uddin S, Bavi PP, Hussain AR, Alsbeih G, Al-Sanea N, Abduljabbar A, et al. Leptin receptor expression in middle eastern colorectal cancer and its potential clinical implication. Carcinogenesis. 2009;30:1832–40.PubMedCrossRef
32.
Janeckova R. The role of leptin in human physiology and pathophysiology. Physiol Res Acad Sci Bohemoslov. 2001;50:443–59.
33.
Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. New Engl J Med. 1996;334:292–5.PubMedCrossRef
34.
Liu L, Zhong R, Wei S, Xiang H, Chen J, Xie D, et al. The leptin gene family and colorectal cancer: interaction with smoking behavior and family history of cancer. PLoS ONE. 2013;8:e60777.PubMedCentralPubMedCrossRef
35.
Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E, et al. Role of leptin in the neuroendocrine response to fasting. Nature. 1996;382:250–2.PubMedCrossRef
36.
Chua Jr SC, Chung WK, Wu-Peng XS, Zhang Y, Liu SM, Tartaglia L, et al. Phenotypes of mouse diabetes and rat fatty due to mutations in the ob (leptin) receptor. Science. 1996;271:994–6.PubMedCrossRef
37.
38.
Lin J, Barb CR, Matteri RL, Kraeling RR, Chen X, Meinersmann RJ, et al. Long form leptin receptor mRNA expression in the brain, pituitary, and other tissues in the pig. Dom Animal Endocrinol. 2000;19:53–61.CrossRef
39.
Caprio M, Fabbrini E, Isidori AM, Aversa A, Fabbri A. Leptin in reproduction. Trends Endocrinol Metabol TEM. 2001;12:65–72.CrossRef
40.
Bartucci M, Svensson S, Ricci-Vitiani L, Dattilo R, Biffoni M, Signore M, et al. Obesity hormone leptin induces growth and interferes with the cytotoxic effects of 5-fluorouracil in colorectal tumor stem cells. Endocrine Rel Cancer. 2010;17:823–33.CrossRef
41.
Birmingham JM, Busik JV, Hansen-Smith FM, Fenton JI. Novel mechanism for obesity-induced colon cancer progression. Carcinogenesis. 2009;30:690–7.PubMedCrossRef
42.
Amemori S, Ootani A, Aoki S, Fujise T, Shimoda R, Kakimoto T, et al. Adipocytes and preadipocytes promote the proliferation of colon cancer cells in vitro. Am J Physiol Gastrointest Liver Physiol. 2007;292:G923–9.PubMedCrossRef
43.
Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D, et al. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res. 2007;67:2497–507.PubMedCentralPubMedCrossRef
44.
Huang XF, Chen JZ. Obesity, the PI3K/AKT signal pathway and colon cancer. Obes Rev. 2009;10:610–16.PubMedCrossRef
45.
Ogunwobi OO, Beales IL. Cyclo-oxygenase-independent inhibition of apoptosis and stimulation of proliferation by leptin in human colon cancer cells. Dig Dis Sci. 2007;52:1934–45.PubMedCrossRef
46.
Bjorbaek C, Uotani S, da Silva B, Flier JS. Divergent signaling capacities of the long and short isoforms of the leptin receptor. J Biol Chem. 1997;272:32686–95.PubMedCrossRef
47.
Sharma D, Saxena NK, Vertino PM, Anania FA. Leptin promotes the proliferative response and invasiveness in human endometrial cancer cells by activating multiple signal-transduction pathways. Endocrine Rel Cancer. 2006;13:629–40.CrossRef
48.
Deo DD, Rao AP, Bose SS, Ouhtit A, Baliga SB, Rao SA, et al. Differential effects of leptin on the invasive potential of androgen-dependent and -independent prostate carcinoma cells. J Biomed Biotechnol. 2008;2008:163902.PubMedCentralPubMedCrossRef
49.
Gao J, Tian J, Lv Y, Shi F, Kong F, Shi H, et al. Leptin induces functional activation of cyclooxygenase-2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells. Cancer Sci. 2009;100:389–95.PubMedCrossRef
50.
Beales IL, Ogunwobi OO. Leptin synergistically enhances the anti-apoptotic and growth-promoting effects of acid in oe33 oesophageal adenocarcinoma cells in culture. Mol Cell Endocrinol. 2007;274:60–8.PubMedCrossRef
51.
Quintas-Cardama A, Verstovsek S. Molecular pathways: JAK/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res. 2013;19:1933–40.PubMedCrossRef
52.
Yu JH, Kim H. Role of Janus kinase/signal transducers and activators of transcription in the pathogenesis of pancreatitis and pancreatic cancer. Gut Liver. 2012;6:417–22.PubMedCentralPubMedCrossRef
53.
Singh N, Hussain S, Bharadwaj M, Kakkar N, Singh SK, Sobti RC. Overexpression of signal transducer and activator of transcription (stat-3 and stat-5) transcription factors and alteration of suppressor of cytokine signaling (socs-1) protein in prostate cancer. J Recept Signal Transduct Res. 2012;32:321–27.PubMedCrossRef
54.
Ma XT, Wang S, Ye YJ, Du RY, Cui ZR, Somsouk M. Constitutive activation of STAT3 signaling pathway in human colorectal carcinoma. World J Gastroentorol WJG. 2004;10:1569–73.
55.
Osaki LH, Gama P. Mapks and signal transduction in the control of gastrointestinal epithelial cell proliferation and differentiation. Int J Mol Sci. 2013;14:10143–61.PubMedCentralPubMedCrossRef
56.
Taylor CA, Zheng Q, Liu Z, Thompson JE. Role of p38 and jnk mapk signaling pathways and tumor suppressor p53 on induction of apoptosis in response to ad-eif5a1 in a549 lung cancer cells. Mol Cancer. 2013;12:35.PubMedCentralPubMedCrossRef
57.
Weston CR, Lambright DG, Davis RJ. Signal transduction. MAP kinase signaling specificity. Science. 2002;296:2345–7.PubMedCrossRef
58.
Hegyi K, Fulop K, Kovacs K, Toth S, Falus A. Leptin-induced signal transduction pathways. Cell Biol Int. 2004;28:159–69.PubMedCrossRef
59.
van den Brink GR, O’Toole T, Hardwick JC, van den Boogaardt DE, Versteeg HH, van Deventer SJ, et al. Leptin signaling in human peripheral blood mononuclear cells, activation of p38 and p42/44 mitogen-activated protein (map) kinase and p70 s6 kinase. Mol Cell Biol Res Comm MCBRC. 2000;4:144–50.CrossRef
60.
Dreyer MG, Juge-Aubry CE, Gabay C, Lang U, Rohner-Jeanrenaud F, Dayer JM, et al. Leptin activates the promoter of the interleukin-1 receptor antagonist through p42/44 mitogen-activated protein kinase and a composite nuclear factor kappa b/pu.1 binding site. Biochem J. 2003;370:591–9.PubMedCrossRef
61.
Ogunwobi O, Mutungi G, Beales IL. Leptin stimulates proliferation and inhibits apoptosis in barrett’s esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-e2-mediated transactivation of the epidermal growth factor receptor and c-jun nh2-terminal kinase activation. Endocrinology. 2006;147:4505–16.PubMedCrossRef
62.
Sun Y, Sinicrope FA. Selective inhibitors of mek1/erk44/42 and p38 mitogen-activated protein kinases potentiate apoptosis induction by sulindac sulfide in human colon carcinoma cells. Mol Cancer Ther. 2005;4:51–9.PubMed
63.
Nishihara H, Hwang M, Kizaka-Kondoh S, Eckmann L, Insel PA. Cyclic amp promotes camp-responsive element-binding protein-dependent induction of cellular inhibitor of apoptosis protein-2 and suppresses apoptosis of colon cancer cells through erk1/2 and p38 mapk. J Biol Chem. 2004;279:26176–83.PubMedCrossRef
64.
Chan UP, Lee JF, Wang SH, Leung KL, Chen GG. Induction of colon cancer cell death by 7-hydroxystaurosporine (ucn-01) is associated with increased p38 mapk and decreased bcl-xl. Anti Canc Drugs. 2003;14:761–6.CrossRef
65.
Lee EJ, Park HG, Kang HS. Sodium salicylate induces apoptosis in hct116 colorectal cancer cells through activation of p38mapk. Int J Oncol. 2003;23:503–8.PubMed
66.
Hussain AR, Ahmed SO, Ahmed M, Khan OS, Al Abdulmohsen S, Platanias LC, et al. Cross-talk between nfkb and the PI3-kinase/AKT pathway can be targeted in primary effusion lymphoma (pel) cell lines for efficient apoptosis. PLoS ONE. 2012;7:e39945.PubMedCentralPubMedCrossRef
67.
Li W, Wang H, Kuang CY, Zhu JK, Yu Y, Qin ZX, et al. An essential role for the id1/pi3k/akt/nfkb/survivin signalling pathway in promoting the proliferation of endothelial progenitor cells in vitro. Mol Cell Biochem. 2012;363:135–45.PubMedCentralPubMedCrossRef
68.
Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene. 1999;18:6938–47.PubMedCrossRef
69.
Carpenter CL, Duckworth BC, Auger KR, Cohen B, Schaffhausen BS, Cantley LC. Purification and characterization of phosphoinositide 3-kinase from rat liver. J Biol Chem. 1990;265:19704–11.PubMed
70.
Chen HC, Guan JL. Association of focal adhesion kinase with its potential substrate phosphatidylinositol 3-kinase. Proc Natl Acad Sci U S A. 1994;91:10148–52.PubMedCentralPubMedCrossRef
71.
72.
Jiang BH, Aoki M, Zheng JZ, Li J, Vogt PK. Myogenic signaling of phosphatidylinositol 3-kinase requires the serine-threonine kinase akt/protein kinase b. Proc Natl Acad Sci U S A. 1999;96:2077–81.PubMedCentralPubMedCrossRef
73.
Uddin S, Bu R, Ahmed M, Abubaker J, Al-Dayel F, Bavi P, et al. Overexpression of leptin receptor predicts an unfavorable outcome in middle eastern ovarian cancer. Mol Cancer. 2009;8:74.PubMedCentralPubMedCrossRef
74.
Uddin S, Bavi P, Siraj AK, Ahmed M, Al-Rasheed M, Hussain AR, et al. Leptin-r and its association with PI3K/AKT signaling pathway in papillary thyroid carcinoma. Endocrine Rel Cancer. 2010;17:191–202.CrossRef
75.
Wang D, Chen J, Chen H, Duan Z, Xu Q, Wei M, et al. Leptin regulates proliferation and apoptosis of colorectal carcinoma through PI3K/AKT/mTOR signalling pathway. J Biosci. 2012;37:91–101.PubMedCrossRef
76.
Rao CV, Janakiram NB, Mohammed A. Lipoxygenase and cyclooxygenase pathways and colorectal cancer prevention. Curr Colorectal Cancer Rep. 2012;8:316–24.PubMedCentralPubMedCrossRef
77.
Muller-Decker K. Cyclooxygenase-dependent signaling is causally linked to non-melanoma skin carcinogenesis: pharmacological, genetic, and clinical evidence. Canc Metastasis Rev. 2011;30:343–61.CrossRef
78.
Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem. 2001;276:18563–69.PubMedCrossRef
79.
Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93:705–16.PubMedCrossRef
80.
Perlikos F, Harrington KJ, Syrigos KN. Key molecular mechanisms in lung cancer invasion and metastasis: a comprehensive review. Crit Rev Oncol Hematol. 2013;87:1–11.PubMedCrossRef
81.
Bhave SL, Teknos TN, Pan Q. Molecular parameters of head and neck cancer metastasis. Crit Rev Eukaryot Gen Expr. 21:143–53.
82.
Salzmann S, Seher A, Trebing J, Weisenberger D, Rosenthal A, Siegmund D, et al. Fibroblast growth factor inducible (fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity. J Biol Chem. 2013;288:13455–66.PubMedCrossRef
83.
Sarfstein R, Werner H. Minireview: nuclear insulin and insulin-like growth factor-1 receptors: a novel paradigm in signal transduction. Endocrinology. 2013;154:1672–79.PubMedCrossRef
84.
Chan CM, Chang HH, Wang VC, Huang CL, Hung CF. Inhibitory effects of resveratrol on pdgf-bb-induced retinal pigment epithelial cell migration via pdgfrbeta, pi3k/akt and mapk pathways. PloS ONE. 2013;8:e56819.PubMedCentralPubMedCrossRef
85.
Stattin P, Palmqvist R, Soderberg S, Biessy C, Ardnor B, Hallmans G, et al. Plasma leptin and colorectal cancer risk: a prospective study in northern sweden. Oncol Rep. 2003;10:2015–21.PubMed
86.
Sierra-Honigmann MR, Nath AK, Murakami C, Garcia-Cardena G, Papapetropoulos A, Sessa WC, et al. Biological action of leptin as an angiogenic factor. Science. 1998;281:1683–6.PubMedCrossRef
87.
Hardwick JC, Van Den Brink GR, Offerhaus GJ, Van Deventer SJ, Peppelenbosch MP. Leptin is a growth factor for colonic epithelial cells. Gastroenterology. 2001;121:79–90.PubMedCrossRef
88.
Attoub S, Noe V, Pirola L, Bruyneel E, Chastre E, Mareel M, et al. Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, rho-, and rac-dependent signaling pathways. FASEB J. 2000;14:2329–38.PubMedCrossRef
89.
Liu Z, Uesaka T, Watanabe H, Kato N. High fat diet enhances colonic cell proliferation and carcinogenesis in rats by elevating serum leptin. Int J Oncol. 2001;19:1009–14.PubMed
90.
Fox SB, Gasparini G, Harris AL. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol. 2001;2:278–89.PubMedCrossRef
Metadaten
Titel
Role of dysregulated expression of leptin and leptin receptors in colorectal carcinogenesis
verfasst von
Shahab Uddin
Azhar R. Hussain
Omar S. Khan
Khawla S. Al-Kuraya
Publikationsdatum
01.02.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 2/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1166-4

Weitere Artikel der Ausgabe 2/2014

Tumor Biology 2/2014 Zur Ausgabe

Research Article

Smoking and hOGG1 Ser326Cys polymorphism contribute to lung cancer risk: evidence from a meta-analysis

Research Article

The effect of IGF-I receptor blockade for human esophageal squamous cell carcinoma and adenocarcinoma

Research Article

Association of COX2 gene hypomethylation with intestinal type gastric cancer in samples of patients from northern Brazil

Research Article

Associations between vascular endothelial growth factor polymorphisms and prostate cancer risk: a meta-analysis

Research Article

Association of XRCC5 VNTR polymorphism with the development of chronic myeloid leukemia

Review

A critical review on HE4 performance in endometrial cancer: where are we now?

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise